Standard of Care sensibility: Rituximab = yes (30mg/kg)
Acquired resistance to: Rituximab
Toledo cells
Human Toledo cells were isolated from the peripheral blood of a patient with non-hogkin’s DLBC lymphoma.
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere. The mice bearing Toledo tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the Toledo cells as xenograft Mean ± SEM (n=3; take rate 100%)
Antineo can also perform an intra-medullar implantation.
Standard-Of-Care Drug Responses
rituximab 30 mg/kg qw → Response
Figure 2: (View PDF)
Effect of rituximab treatment on Toledo tumour growth Mean ± SEM (n=3 per group; take rate 100%)
A Toledo resistant to rituximab model, developed in vivo without genetic modifications, are available at Antineo (model ID Toledo rituxR).